Literature DB >> 21310922

Regulation of S100A10 by the PML-RAR-α oncoprotein.

Paul A O'Connell1, Patricia A Madureira, Jason N Berman, Robert S Liwski, David M Waisman.   

Abstract

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia that results from the expression of the promyelocytic leukemia-retinoic acid receptor α (PML-RAR-α) oncoprotein. It is characterized by severe hemorrhagic complications due in part to excessive fibrinolysis, resulting from the excessive generation of the fibrinolytic enzyme, plasmin, at the cell surface of the PML cells. The treatment of patients with all-trans retinoic acid (ATRA) effectively ameliorates the disease by promoting the destruction of the PML-RAR-α oncoprotein. In the present study we show for the first time that the plasminogen receptor, S100A10, is present on the extracellular surface of APL cells and is rapidly down-regulated in response to all-trans retinoic acid. The loss of S100A10 is concomitant with a loss in fibrinolytic activity. Furthermore, the induced expression of the PML-RAR-α oncoprotein increased the expression of cell surface S100A10 and also caused a dramatic increase in fibrinolytic activity. Depletion of S100A10 by RNA interference effectively blocked the enhanced fibrinolytic activity observed after induction of the PML-RAR-α oncoprotein. These experiments show that S100A10 plays a crucial role in the generation of plasmin leading to fibrinolysis, thus providing a link to the clinical hemorrhagic phenotype of APL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21310922     DOI: 10.1182/blood-2010-07-298851

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  Monoclonal antibodies against receptor-induced binding sites detect cell-bound plasminogen in blood.

Authors:  Jordi Félez; Mercè Jardí; Pere Fàbregas; Robert J Parmer; Lindsey A Miles
Journal:  Blood       Date:  2012-05-30       Impact factor: 22.113

Review 2.  The annexin A2 system and vascular homeostasis.

Authors:  Elle C Flood; Katherine A Hajjar
Journal:  Vascul Pharmacol       Date:  2011-03-29       Impact factor: 5.773

Review 3.  Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2020-09-09       Impact factor: 2.490

4.  Distinct prognostic values of Annexin family members expression in acute myeloid leukemia.

Authors:  Y Niu; X Yang; Y Chen; X Jin; Y Xie; Y Tang; L Li; S Liu; Y Guo; X Li; L Duan; H Wang
Journal:  Clin Transl Oncol       Date:  2019-01-29       Impact factor: 3.405

Review 5.  Fibrinolysis and the control of blood coagulation.

Authors:  John C Chapin; Katherine A Hajjar
Journal:  Blood Rev       Date:  2014-09-16       Impact factor: 8.250

6.  Annexin A2-S100A10 heterotetramer is upregulated by PML/RARα fusion protein and promotes plasminogen-dependent fibrinolysis and matrix invasion in acute promyelocytic leukemia.

Authors:  Dan Huang; Yan Yang; Jian Sun; Xiaorong Dong; Jiao Wang; Hongchen Liu; Chengquan Lu; Xueyu Chen; Jing Shao; Jinsong Yan
Journal:  Front Med       Date:  2017-07-08       Impact factor: 4.592

Review 7.  Annexin A2 system in human biology: cell surface and beyond.

Authors:  Min Luo; Katherine A Hajjar
Journal:  Semin Thromb Hemost       Date:  2013-03-12       Impact factor: 4.180

Review 8.  The Biology of Annexin A2: From Vascular Fibrinolysis to Innate Immunity.

Authors:  Katherine A Hajjar
Journal:  Trans Am Clin Climatol Assoc       Date:  2015

Review 9.  Functions of S100 proteins.

Authors:  R Donato; B R Cannon; G Sorci; F Riuzzi; K Hsu; D J Weber; C L Geczy
Journal:  Curr Mol Med       Date:  2013-01       Impact factor: 2.222

Review 10.  Bleeding Disorders in Primary Fibrinolysis.

Authors:  Massimo Franchini; Marco Zaffanello; Pier Mannuccio Mannucci
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.